mdxhealth to Acquire Bio-Techne’s Exosome Diagnostics Business (ExoDx Prostate)
August 5, 2025
Bio-Techne Corporation has reached an agreement for mdxhealth SA to acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test and CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to proprietary exosome-based technology for ongoing kit development, and expects the transaction to be completed in the first quarter of fiscal 2026.
- Buyers
- mdxhealth SA
- Targets
- Exosome Diagnostics Inc., ExoDx Prostate (EPI) test, Bio-Techne Exosome Diagnostics business (including CLIA-certified clinical laboratory and related assets)
- Sellers
- Bio-Techne Corporation
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Eurobio Scientific Acquires CareDx Lab Products Division
April 16, 2026
Healthcare Services
Eurobio Scientific entered into a definitive agreement to acquire CareDx’s Lab Products transplant lab products division for €145 million (about $170 million) in cash. The deal will integrate the acquired Lab Products portfolio into Eurobio’s GenDx operations and is intended to expand GenDx’s comprehensive transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions.
-
Genexine Announces Merger with EPD Biotherapeutics (EPD Bio)
July 4, 2024
Biotechnology
Genexine, a clinical-stage Korean biopharmaceutical company, announced a small-scale merger with EPD Biotherapeutics (EPD Bio) to strengthen its drug development pipeline. The merger is intended to add PROTAC/bioPROTAC (bioPROTAC via EPDegTM mRNA-LNP) technology talent and expand Genexine’s R&D capabilities, with EPD Bio’s founder joining Genexine to lead R&D.
-
Ginkgo Bioworks Acquires Proof Diagnostics
February 28, 2024
Biotechnology
Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.
-
Biosynex S.A. Acquires ProciseDx Inc.
June 13, 2023
Medical Devices
French diagnostics company Biosynex S.A. has acquired ProciseDx Inc., a U.S.-based point-of-care in vitro diagnostics company. The acquisition will help Biosynex commercialize ProciseDx's therapeutic drug monitoring (TDM) tests for infliximab and adalimumab in the United States and accelerate point-of-care biologic drug monitoring.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
Tesis Biosciences Acquires Genome Explorations
February 16, 2022
Biotechnology
Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.